Clinical trial
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are…
NCT00265759 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00265759 |
|---|---|
| Title | Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer |
| Official title | A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH Cancer and Leukemia Group B |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | anastrozole, exemestane, letrozole, Therapeutic Conventional Surgery |
| Enrollment | 622 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2012 |
| Completion | Nov 27, 2019 |
| First posted | Dec 15, 2005 |
| Last update posted | Apr 23, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: